173 related articles for article (PubMed ID: 4147555)
1. The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients.
Das KM; Eastwood MA; McManus JP; Sircus W
Gut; 1973 Aug; 14(8):631-41. PubMed ID: 4147555
[TBL] [Abstract][Full Text] [Related]
2. Steady-state kinetics of 5-aminosalicylic acid and sulfapyridine during sulfasalazine prophylaxis in ulcerative colitis.
Bondesen S; Nielsen OH; Schou JB; Jensen PH; Lassen LB; Binder V; Krasilnikoff PA; Danø P; Hansen SH; Rasmussen SN
Scand J Gastroenterol; 1986 Aug; 21(6):693-700. PubMed ID: 2875518
[TBL] [Abstract][Full Text] [Related]
3. The metabolism of salicylazosulphapyridine in ulcerative colitis: II The relationship between metabolites and the progress of the disease studied in outpatients.
Gut; 1973 Aug; 14(8):637-41. PubMed ID: 18668841
[TBL] [Abstract][Full Text] [Related]
4. Sulfasalazine metabolite pharmacokinetics in pediatric patients with inflammatory bowel disease: effects of disease activity, acetylator phenotype, and age.
Clarke DF; George D; Milsap RL; Pogonowska-Wala E; Owerbach J; Lebenthal E; Jusko WJ
Pediatr Pharmacol (New York); 1982; 2(4):323-33. PubMed ID: 6152489
[TBL] [Abstract][Full Text] [Related]
5. The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man.
Azadkhan AK; Truelove SC; Aronson JK
Br J Clin Pharmacol; 1982 Apr; 13(4):523-8. PubMed ID: 6121576
[TBL] [Abstract][Full Text] [Related]
6. The effect of the acetylator phenotype on the metabolism of sulphasalazine in man.
Azad Khan AK; Nurazzaman M; Truelove SC
J Med Genet; 1983 Feb; 20(1):30-6. PubMed ID: 6133000
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the absorption and metabolism of sulphasalazine and acrylic-coated 5-amino salicylic acid in normal subjects and patients with colitis.
Dew MJ; Ebden P; Kidwai NS; Lee G; Evans BK; Rhodes J
Br J Clin Pharmacol; 1984 Apr; 17(4):474-6. PubMed ID: 6144318
[TBL] [Abstract][Full Text] [Related]
8. Influence of intestinal transit time on azo-reduction of salicylazosulphapyridine (Salazopyrin).
van Hees PA; Tuinte JH; van Rossum JM; van Tongeren JH
Gut; 1979 Apr; 20(4):300-4. PubMed ID: 36332
[TBL] [Abstract][Full Text] [Related]
9. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
[TBL] [Abstract][Full Text] [Related]
10. Different therapy for different types of ulcerative colitis in China.
Jiang XL; Cui HF
World J Gastroenterol; 2004 May; 10(10):1513-20. PubMed ID: 15133864
[TBL] [Abstract][Full Text] [Related]
11. Acetylation polymorphism of sulfapyridine in patients with ulcerative colitis and Crohn's disease.
Das KM; Eastwood MA
Clin Pharmacol Ther; 1975 Nov; 18(5 Pt 1):514-20. PubMed ID: 241531
[TBL] [Abstract][Full Text] [Related]
12. The role of the colon in the metabolism of salicylazosulphapyridine.
Das KM; Eastwood MA; McManus JP; Sircus W
Scand J Gastroenterol; 1974; 9(2):137-41. PubMed ID: 4150441
[No Abstract] [Full Text] [Related]
13. Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis.
Lauritsen K; Hansen J; Ryde M; Rask-Madsen J
Gastroenterology; 1984 Jun; 86(6):1496-500. PubMed ID: 6143704
[TBL] [Abstract][Full Text] [Related]
14. Comparative pharmacokinetics of sulphasalazine and sulphapyridine after rectal and oral administration to patients with ulcerative colitis.
Allgayer H; Kruis W; Eisenburg J; Paumgartner G
Eur J Clin Pharmacol; 1984; 26(2):275-7. PubMed ID: 6144549
[TBL] [Abstract][Full Text] [Related]
15. The effect of age and acetylator phenotype on the pharmacokinetics of sulfasalazine in patients with rheumatoid arthritis.
Taggart AJ; McDermott BJ; Roberts SD
Clin Pharmacokinet; 1992 Oct; 23(4):311-20. PubMed ID: 1356683
[TBL] [Abstract][Full Text] [Related]
16. Steady-state pharmacokinetics of enteric coated 5-amino-salicylic acid tablets in healthy volunteers and in patients with Crohn's disease or ulcerative colitis.
Norlander B; Gotthard R; Ström M
Aliment Pharmacol Ther; 1991 Jun; 5(3):291-300. PubMed ID: 1888828
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.
Klotz U
Clin Pharmacokinet; 1985; 10(4):285-302. PubMed ID: 2864155
[TBL] [Abstract][Full Text] [Related]
18. Genetically determined variability in acetylation and oxidation. Therapeutic implications.
Clark DW
Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetics of sulphasalazine.
Das KM; Dubin R
Clin Pharmacokinet; 1976; 1(6):406-25. PubMed ID: 15752
[TBL] [Abstract][Full Text] [Related]
20. Further studies of sulphasalazine metabolism in the treatment of ulcerative colitis.
Cowan GO; Das KM; Eastwood MA
Br Med J; 1977 Oct; 2(6094):1057-9. PubMed ID: 21720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
